Article

Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women.

Department of Global Health
The Journal of Infectious Diseases (Impact Factor: 5.85). 03/2013; DOI: 10.1093/infdis/jit093
Source: PubMed

ABSTRACT Background. HIV infection is a risk factor for Epstein-Barr virus (EBV)-associated lymphomas. Characterizing primary infection may elucidate risk factors for malignancy.Methods. To describe clinical and virologic manifestations of primary EBV infection among infants born to HIV-infected women. Specimens were utilized from a cohort study conducted in Nairobi, Kenya. HIV-1 and EBV viral load were measured serially in plasma. EBV serology was performed on EBV DNA-negative infants. Monthly clinical examinations were performed by pediatricians.Results. The probability of EBV infection by 1 year of age was 0.78 (95%CI:0.67-0.88) in HIV-infected and 0.49 (95%CI:0.35-0.65) in HIV-uninfected infants (p<0.0001). At 2 years, probability of EBV infection was 0.96 (95%CI:0.89-0.99) in HIV-infected infants. Peak EBV loads were higher in HIV-infected versus HIV-uninfected infants (median 2.6 versus 2.1&emsp14;log10copies/ml; p<0.0001). The majority of HIV-infected infants had detectable EBV DNA for >3 months (79%). Primary EBV infection was associated with cough, fever, otitis media, pneumonia, hepatomegaly, splenomegaly, and hospitalization in HIV-1 infected infants, and conjunctivitis and rhinorrhea in HIV-uninfected infants.Conclusions. EBV infection occurs early in infants born to HIV-infected women. HIV infection was associated with more frequent and higher quantity EBV DNA detection. Primary EBV may manifest as severe disease in HIV-infected infants.

1 Bookmark
 · 
87 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Primary Epstein-Barr virus (EBV) infection affects the host differently according to when in life it is acquired. Understanding risk factors for infection could be important for disease prevention and the age-specific prevalence of infection must be known to optimize use of a prophylactic vaccine. Methods. Children 18 months to 19.9 years old who had blood drawn for medical indications during an outpatient visit were eligible. Sera were tested for IgG antibodies against EBV viral capsid antigen by enzyme immunoassay. Family demographic and socioeconomic data were obtained via scripted telephone questionnaires. Results. Consent was given for 876 (96%) of 914 subjects approached. Sera were available for 782 (89%) of 876 subjects and demographic/socioeconomic data obtained for 705 (90%) of them. Antibody prevalence, adjusted for age and sex, was: non-Hispanic blacks, 74%; Asians, 62%, multiracial children, 54%; Hispanics, 50%; non-Hispanic whites, 26%. The pattern of increases in antibody prevalence with age differed significantly by race/ethnicity, and was most divergent in the 2 youngest age groups. Adjusted EBV antibody prevalence decreased with greater household education among non-Hispanic whites, but was not associated with any other socioeconomic factor. In 42 (82%) of 51 families with >1 child in the study, the siblings' EBV antibody status was concordant (bootstrap P<.001). Conclusions. Racial/ethnic differences in EBV antibody prevalence and concordance of antibody status among siblings prompt us to speculate that both genetics and family environment contribute to acquisition of EBV infection. The ideal age to give a prophylactic vaccine may differ according race/ethnicity.
    Clinical Infectious Diseases 05/2014; 59(4). DOI:10.1093/cid/ciu342 · 9.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-infected infants in sub-Saharan Africa have rapid disease progression. We hypothesized that co-infection with cytomegalovirus (CMV) or Epstein Barr virus (EBV) increases mortality in HIV-infected infants. 257 antiretroviral therapy-naïve HIV-infected Zimbabwean infants were tested for CMV and EBV at 6 weeks of age by real-time PCR; if positive, birth samples were retrieved where available to distinguish congenital and postnatal infection. The impact of co-infection on mortality through 6 months was estimated using Kaplan-Meier and Cox proportional hazards methods. At 6 weeks, 203/257 (79%) HIV-infected infants were CMV-positive; 27 (11%) had congenital CMV, 108 (42%) postnatal CMV and 68 (26%) indeterminate timing of infection. By 6 months, 37/108 (34%) infants with postnatal CMV versus 16/54 (30%) CMV-negative infants died (adjusted hazard ratio (aHR) 1.1 [95%CI 0.6, 2.2]). At 6 weeks, 33/257 (13%) HIV-infected infants had EBV co-infection; 6 (2%) had congenital EBV, 18 (7%) postnatal EBV and 9 (4%) indeterminate timing of infection. By 6 months, 5/18 (28%) infants with postnatal EBV versus 72/224 (32%) EBV-negative infants died (aHR 0.8 [95%CI 0.3, 2.3]). The vast majority of HIV-infants had acquired CMV by 6 weeks, and EBV co-infection occurred earlier than expected, with one in eight HIV-infected infants positive for EBV by 6 weeks. There was a high prevalence of congenital CMV infection and we identified 6 infants with congenital EBV infection, which has not previously been reported in Africa or in the context of HIV infection. Neither CMV nor EBV co-infection was associated with increased mortality.
    PLoS ONE 12/2014; 9(12):e114870. DOI:10.1371/journal.pone.0114870 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Epstein-Barr Virus (EBV) is involved in a wide range of malignancies, particularly in immunocompromised subjects. In Africa, EBV primary infection occurs during early childhood, but little is known about EBV load in HIV-1-infected children.Methods. Dried Blood Spot samples from 213 HIV-1-infected children, 140 on antiretroviral therapy (ART), were collected at the Nsambya Hospital in Kampala, Uganda. Nucleic acids were extracted and analysed for quantification of EBV types 1 and 2, 16S ribosomal DNA (16S rDNA), a marker of microbial translocation, and HIV-1 RNA.Results. Ninety-two of 140(66%) children on ART and 57 of 73(78%) ART-naive children had detectable EBV-DNA levels. Co-infection with both EBV types was less frequent in ART-treated than in ART-naive children (OR=0.54[95%CI 0.30-0.98];P= .042). EBV-DNA levels were lower in the former (3.99±0.59 vs 4.22±0.54 log10 copies/ml;P= .006) and tended to be inversely associated with time on ART. EBV-DNA levels were higher in children with HIV-1 RNA>3 log10 copies/ml of blood (regression coefficient=0.32[95%CI 0.05-0.59];P= .020) and correlated with circulating 16S rDNA levels(rs=0.25[95%CI 0.02-0.46];P= .031).Conclusions. These findings suggest that ART, by limiting HIV-1 replication, microbial translocation and related immune activation, prevents super-infection with both EBV types and keeps EBV viremia down, thus potentially reducing the risk of EBV-associated lymphomas.
    The Journal of Infectious Diseases 02/2014; 210(3). DOI:10.1093/infdis/jiu099 · 5.85 Impact Factor